A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Phase 2

Recruiting

• Conditions: Overweight or Obesity; CKD; Type 2 Diabetes

• Registration Number: NCT05936151
• Lead Sponsor: Eli Lilly and Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-6-30
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Inclusion Criteria:<br><br> - Have a body mass index (BMI) =27 kilogram/square meter (kg/m²)<br><br> - Have either<br><br> - no T2D with an HbA1c < 6.5% or<br><br> - have T2D with an HbA1c = 9.5% and treated with diet and exercise only or with<br> stable doses of up to 3 oral antihyperglycemic medications, with or without<br> basal insulin for at least 90 days before screening.<br><br> - Have been diagnosed with chronic kidney disease (CKD).<br><br>Exclusion Criteria:<br><br> - Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90<br> days before screening.<br><br> - Have used in 90 days before the screening any of the following antihyperglycemic<br> class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like<br> peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting<br> or rapid acting insulins or U500 Insulin<br><br> - Have a prior or planned surgical treatment for obesity<br><br> - Have Type 1 Diabetes (T1D)<br><br> - Have acute or chronic hepatitis<br><br> - Have a history of malignant disease within 5 years before screening.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Glomerular Filtration Rate (mGFR)